Increased Disease Prevalence Increases Pretest Probability

The correct answer is D: increased disease prevalence would increase the pretest probability. 1, 2

Understanding the Relationship Between Prevalence and Test Characteristics

Sensitivity and specificity are intrinsic properties of a diagnostic test that remain stable regardless of disease prevalence in the population being tested. 1, 2
Likelihood ratios (both positive and negative) are also prevalence-independent test characteristics that do not change whether applied to populations with 10% or 80% disease prevalence. 1

Positive predictive value (PPV) and negative predictive value (NPV) are strongly influenced by disease prevalence in the population being tested. 3, 1, 2
Pretest probability is directly equivalent to disease prevalence—they are the same concept expressed differently. 3, 1

This statement is backwards: decreased disease prevalence actually increases NPV, not reduces it. 1
In populations with low disease prevalence, NPV tends to be higher, meaning negative tests are more reliable for ruling out disease. 1
For example, in a population with 20% disease prevalence using a test with 90% sensitivity and 90% specificity, the NPV is approximately 97%. 1
When prevalence drops further to very low levels (≈1%), NPV can exceed 99% even with modest test performance. 1

This is false: likelihood ratios are prevalence-independent characteristics of the test itself. 1
A test with LR+ = 10 and LR- = 0.1 maintains these values whether applied to populations with 10% or 80% disease prevalence. 1

This is the opposite of reality: increased disease prevalence increases PPV, not reduces it. 3, 2, 4
The mathematical relationship is: PPV = [sensitivity/(1-specificity)] × prevalence, demonstrating that PPV is directly proportional to prevalence. 2, 4
In Alzheimer's disease biomarker testing, when prevalence increases from 20% to 80%, the PPV rises dramatically (from lower values to approaching 93.7% or higher). 3, 1
Conversely, in low-prevalence settings (<20%), even excellent tests produce markedly lower PPV (≈69%), requiring confirmatory testing. 1

Pretest probability and disease prevalence are mathematically identical concepts. 3, 1
When disease prevalence in a population increases, the pretest probability for any individual from that population automatically increases by the same amount. 3, 1
Clinical examples demonstrate this principle: in tuberculosis contact tracing, close contacts have 25-50% pretest probability (prevalence) of infection, while the general U.S. population has only 5-10% pretest probability. 3

In high-prevalence populations (≥50%), tests are better at "ruling in" disease (high PPV) but worse at "ruling out" disease (lower NPV). 1
In low-prevalence populations (<20%), tests are better at "ruling out" disease (high NPV) but worse at "ruling in" disease (lower PPV). 1, 5

A common error is assuming that high NPV reflects superior intrinsic test characteristics rather than recognizing it as primarily a function of low disease prevalence. 1
Clinicians must never apply NPV or PPV values derived from one prevalence context to populations with different prevalence, as this leads to erroneous clinical decisions. 1, 2
In screening programs for low-prevalence conditions, even highly specific tests (99% specificity) generate more false-positive than true-positive results. 3, 4, 5

Before ordering any diagnostic test, clinicians should estimate the pretest probability using clinical prediction rules, patient demographics, symptoms, and risk factors. 3, 1
Tests intended to rule out disease should only be used when pretest probability is ≤50%; above this threshold, even highly accurate tests cannot provide sufficiently high NPV. 1
In populations where false positives would cause significant harm, two-step testing approaches are recommended to improve PPV in low-prevalence settings. 2, 4